Odborné zdroje
DIOSMIN A HESPERIDIN
Zvýšení žilního tonu
Ibegbuna V, Nicolaides AN, Sowade O, Leon M, Geroulakos G. Venous elasticity after treatment with Daflon 500 mg. Angiology 1997;48:45-9.
Gargouil YM, Perdrix L, Chapelain B, Gaborieau R. Effects of Daflon 500 mg on bovine vessels ontractility.
Int Angiol 1989;8(4 Suppl):19S-22S.
Tsouderos Y. Venous tone: are the phlebotonic properties predictive of a therapeutic benefit? A comprehensive view of our experience with Daflon 500 mg. Z Kardiol 1991;80(Suppl 7):95-101.
Zánětlivý proces v chlopni a ve stěně žíly
Shoab SS, Porter J, Scurr JH, Coleridge-Smith PD. Endothelial activation response to oral micronised flavonoid therapy in patients with chronic venous disease– a prospective study. Eur J Vasc Endovasc Surg 1999;17:313-8.
Shoab SS, Porter JB, Scurr JH, Coleridge-Smith PD. Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease: a pilot study. J Vasc Surg 2000;31:456-61.
Otok nohou
Frileux C, Gilly R. Activité thérapeutique de Daflon 500 mg dans l’insuffisance veineuse chronique des membres inférieurs. J Int Med 1987;(Suppl 99):36-9. Planchon B. Insuffisance veineuse et Daflon 500 mg. Arteres et Veines 1990;9:376-80.
Chassignolle J-F, Amiel M, Lanfranchi G, Barbe R. Activité thérapeutique de Daflon 500 mg dans ’insuffisance veineuse fonctionnelle. J Int Med 1987;(Suppl 99):32-5.
Bolest nohou
Frileux C, Gilly R. Activité thérapeutique de Daflon 500 mg dans l’insuffisance veineuse chronique des membres inférieurs. J Int Med 1987;(Suppl 99):36-9.
Planchon B. Insuffisance veineuse et Daflon 500 mg. Arteres et Veines 1990;9:376-80.
Rabe E, Agus GB, Roztocil K. Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. Int Angiol 2015;34:428-36.
Biland L, Blattler P, Scheibler P, Studer S, Widmer LK. Zur Therapie sogenannt venoser Beinbeschwerden. (Kontrollierte Doppelblind-Studie zur Untersuchung der therapeutischen Wirksamkeit von Daflon). Vasa 1982;11:53-8.
Těžké nohy
Frileux C, Gilly R. Activité thérapeutique de Daflon 500 mg dans l’insuffisance veineuse chronique des membres inférieurs. J Int Med 1987;(Suppl 99):36-9.
Planchon B. Insuffisance veineuse et Daflon 500 mg. Arteres et Veines 1990;9:376-80.
Chassignolle J-F, Amiel M, Lanfranchi G, Barbe R. Activité thérapeutique de Daflon 500 mg dans l’insuffisance veineuse fonctionnelle. J Int Med 1987;(Suppl 99):32-5.
Hojení bércového vředu
Coleridge-Smith P, Lok C, Ramelet AA. Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg 2005;30:198-208.
Křeče
Frileux C, Gilly R. Activité thérapeutique de Daflon 500 mg dans l’insuffisance veineuse chronique des membres inférieurs. J Int Med 1987;(Suppl 99):36-9.
Planchon B. Insuffisance veineuse et Daflon 500 mg. Arteres et Veines 1990;9:376-80.
Biland L, Blattler P, Scheibler P, Studer S, Widmer LK. Zur Therapie sogenannt venoser Beinbeschwerden. (Kontrollierte Doppelblind-Studie zur Untersuchung der therapeutischen Wirksamkeit von Daflon). Vasa 1982;11:53-8.
Parestézie
Frileux C, Gilly R. Activité thérapeutique de Daflon 500 mg dans l’insuffisance veineuse chronique des membres inférieurs. J Int Med 1987;(Suppl 99):36-9.
Planchon B. Insuffisance veineuse et Daflon 500 mg. Arteres et Veines 1990;9:376-80.
Pálení / svědění nohou
Frileux C, Gilly R. Activité thérapeutique de Daflon 500 mg dans l’insuffisance veineuse chronique des membres inférieurs. J Int Med 1987;(Suppl 99):36-9.
Planchon B. Insuffisance veineuse et Daflon 500 mg. Arteres et Veines 1990;9:376-80
Chassignolle J-F, Amiel M, Lanfranchi G, Barbe R. Activité thérapeutique de Daflon 500 mg dans l’insuffisance veineuse fonctionnelle. J Int Med 1987;(Suppl 99):32-5.
Souhrn příznaků
Kakkos S, Nicolaides AN. Efficacy of purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol 2018 2018 Jan 31 [Epub ahead of print].
RUTIN
Zvýšení žilního tonu
Frick RW. Three treatments for chronic venous insufficiency: escin, hydroxyethylrutoside, and Daflon. Angiology 2000;51:197-205.
RUTOSIDY
Zvýšení žilního tonu
Frick RW. Three treatments for chronic venous insufficiency: escin, hydroxyethylrutoside, and Daflon. Angiology 2000;51:197-205.
Bolest nohou
Aziz Z, Tang WL, Chong NJ, Tho LY. A systematic review of the efficacy and tolerability of hydroxyethylrutosides for improvement of the signs and symptoms of chronic venous insufficiency. J Clin Pharm Ther 2015;40:177-85.
Těžké nohy
Aziz Z, Tang WL, Chong NJ, Tho LY. A systematic review of the efficacy and tolerability of hydroxyethylrutosides for improvement of the signs and symptoms of chronic venous insufficiency. J Clin Pharm Ther 2015;40:177-85.
Křeče
Aziz Z, Tang WL, Chong NJ, Tho LY. A systematic review of the efficacy and tolerability of hydroxyethylrutosides for improvement of the signs and symptoms of chronic venous insufficiency. J Clin Pharm Ther 2015;40:177-85.
ESCIN
Souhrn příznaků
Ramelet AA, Boisseau MR, Allegra C, Nicolaides A, Jaeger K, Carpentier P, et al. Veno-active drugs in the management of chronic venous disease. An international consensus statement: current medical position, prospective views and final resolution. Clin Hemorheol Microcirc 2005;33:309-19.
Nicolaides AN, Allegra C, Bergan J, Bradbury A, Cairols M, Carpentier P, et al. Management of chronic venous disorders of the lower limbs: guidelines according to scientific evidence. Int Angiol 2008;27:1-59.
Zvýšení žilního tonu
Guillaume M, Padioleau F. Veinotonic effect, vascular protection, antiinflammatory and free radical scavenging properties of horse chestnut extract. Arzneimittelforschung 1994;44:25-35.
Otok nohou
Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database Syst Rev 2012;11:CD003230.
Bolest nohou
Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database Syst Rev 2012;11:CD003230.
Cloarec M. Study on the effect of a new vasoprotective Venostasin administered over a period of 2 months in chronic venous insufficiency of the lower limb (data from1992). Data on file (quoted by Pittler and Ernst Ref 110 above).
Friederich HC, Vogelsberg H, Neiss A. [Evaluation of internally effective venous drugs]. Z Hautkr 1978;53:369-74.
Lohr E, Garanin G, Jesau P, Fischer H. [Anti-edemic treatment in chronic venous nsufficiency with tendency to formation of oedema]. MMW Munch Med Wochenschr 1986;128:579-81.
Morales Paris CA, Barros Soares RM. Efficacy and safety on use of dried horse chestnut extract in the treatment of chronic venous insufficiency of the limbs. Revista Brasileira de Medicina 1993;50:1563-5.
Neiss A, Böhm C. [Demonstration of the effectiveness of horse chestnut seed extract in the varicose syndrome complex]. MMW Munch Med Wochenschr 1976;118:213-6.
Rudofsky G, Neiss A, Otto K, Seibel K. [Oedema-protective effect and clinical efficacy of horse chestnut seed extract in a double blind study]. Phlebologie und Proktologie 1986;15:47-54.
Steiner M. Investigation into the oedema reducing and oedema protective effects of horse chestnut seed extract [Untersuchungen zur ödemvermindernden und ödemprotektiven Wirkung von Roßkastaniensamenextrakt]. Phlebologie und Proktologie 1990;19:239-42.
Pálení / svrbění nohou
Rudofsky G, Neiss A, Otto K, Seibel K. [Oedema-protective effect and clinical efficacy of horse chestnut seed extract in a double blind study]. Phlebologie und Proktologie 1986;15:47-54.
Steiner M. Investigation into the oedema reducing and oedema protective effects of horse chestnut seed extract [Untersuchungen zur ödemvermindernden und ödemprotektiven Wirkung von Roßkastaniensamenextrakt]. Phlebologie und Proktologie 1990;19:239-42.
Steiner M, Hillemanns HG.[Tests for anti-oedema action of a venous therapy]. MMW Munch Med Wochenschr 1986;128:551-2.
Diehm C, Schmidt C. Venostasin retard gegen Plazebo und Kompression bei Patienten mit CVI II/IIIA. Final Study Report. Munich: Klinge Pharma GmbH; 2000.
Diehm C, Vollbrecht D, Amendt K, Comberg HU. Medical edema protection – Clinical benefit in patients with chronic deep vein incompetence. VASA 1992;21:188-92.
Diehm C, Trampisch HJ, Lange S, Schmidt C. Comparison of leg compression stocking and oral horsechestnut seed extract therapy in patients with chronic venous insufficiency. Lancet 1996;347:292-4
OXERUTIN
Otok nohou
Maclennan WJ, et al. Hydroxyethylrutosides in elderly patients with chronic venous insufficiency: its efficacy and tolerability. Gerontology 1994;40:45-52.
Bolest nohou
Belcaro G, Rulo A, Candiani C. Evaluation of the microcirculatory effects of Venoruton in patients with chronic venous hypertension by laserdoppler flowmetry, transcutaneous PO2 and PCO2 measurements, leg volumetry and ambulatory venous pressure measurements. Vasa 1989;18:146-51.
Cloarec M, Clement R, Griton P. A double-blind clinical trial of hydroxyethylurosides in the treatment of the symptoms and signs of chronic venous insufficiency. Phlebology 1996;11:76-82.
Pedersen FM1, Hamberg O, Sørensen MD, Neland K. Effect of 0-(beta-hydroxyethyl)-rutoside (Venoruton) on symptomatic venous insufficiency in the lower limbs. Ugeskr Laeger 1992;154:2561-3.
Welsh W, Moriau M, van Gysel JP. A double blind placebo-controlled trial of o-(beta-hydroxyethyl)-rutosidesin patients with chronic venous insufficiency. Basel: Novartis; 1985.
Těžké nohy
Maclennan WJ, et al. Hydroxyethylrutosides in elderly patients with chronic venous insufficiency: its efficacy and tolerability. Gerontology 1994;40:45-52
Petruzzellis V, Troccoli T, Candiani C, Guarisco R, Lospalluti M, Belcaro G, et al. Oxerutins (Venoruton): efficacy in chronic venous insufficiency–a double-blind, randomized, controlled study. Angiology 2002;53:257-63.
Křeče
Maclennan WJ, et al. Hydroxyethylrutosides in elderly patients with chronic venous insufficiency: its efficacy and tolerability. Gerontology 1994;40:45-52
Belcaro G, Rulo A, Candiani C. Evaluation of the microcirculatory effects of Venoruton in patients with chronic venous hypertension by laserdoppler flowmetry, transcutaneous PO2 and PCO2 measurements, leg volumetry and ambulatory venous pressure measurements. Vasa 1989;18:146-51.
Obvod kotníku a lýtka
Maclennan WJ, et al. Hydroxyethylrutosides in elderly patients with chronic venous insufficiency: its efficacy and tolerability. Gerontology 1994;40:45-52.
Cloarec M, Clement R, Griton P. A double-blind clinical trial of hydroxyethylurosides in the treatment of the symptoms and signs of chronic venous insufficiency. Phlebology 1996;11:76-82.
